Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin (NASDAQ: AMRN) reported Q1 2026 results: Total net revenue $45.1M (up 7% vs Q1 2025), product revenue $43.3M, licensing & royalties $1.8M (up 84%), and cash of $307.8M as of March 31, 2026. Operating expenses fell 31% to $29.1M; operating loss narrowed to $(11.3)M and net loss improved to $(10.5)M.
The company generated positive cash flow for a second consecutive quarter, reiterated expectation for full-year 2026 positive cash flow, and cited international partnership-driven European growth and updated clinical guidelines supporting icosapent ethyl.
Amarin (NASDAQ: AMRN) will report first quarter 2026 financial results and host a conference call on Wednesday, April 29, 2026.
The company will release results in pre-market hours and hold a live call at 8:00 a.m. ET, with telephone dial-in, webcast access on the Investor Relations website, and a replay available online until 10/29/26.
Amarin (NASDAQ: AMRN) highlighted ACC Scientific Sessions 2026 findings stressing that elevated triglycerides drive residual cardiovascular risk despite LDL-C control and that icosapent ethyl (IPE) can reduce events when added to statins.
Amarin-supported REDUCE-IT post hoc analysis found significant CV event reduction in extreme and very high-risk patients; plaque-imaging studies EVAPORATE and CHERRY showed favorable coronary plaque effects with EPA.
Amarin (NASDAQ: AMRN) welcomed the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline update endorsing a broader approach to residual cardiovascular risk and recognizing icosapent ethyl (IPE) as an evidence-based adjunct for statin-treated patients with elevated triglycerides. The guideline highlights IPE's role in reducing ASCVD events beyond LDL-C lowering.
Amarin (NASDAQ: AMRN) announced additional REDUCE-IT subgroup analyses and mechanistic EPA data will be presented at the American College of Cardiology Annual Scientific Session & Expo, March 28-30, 2026 in New Orleans.
Highlighted presentations include a REDUCE-IT secondary analysis on patients at extreme cardiovascular risk (oral, March 29, 12:30pm CST) and an EPA inhibition of Lp(a) oxidation poster (March 28, 11:00am CST).
Amarin (NASDAQ: AMRN) highlighted a post hoc REDUCE-IT analysis published March 2026 in the European Journal of Preventive Cardiology showing icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost to hospitalization and death among 8,179 statin-treated participants followed for a median of five years.
The paper underscores patient-centered benefits of IPE (VASCEPA/VAZKEPA) and notes prior REDUCE-IT results influenced guideline inclusion.
Amarin (NASDAQ: AMRN) reported Q4 and full‑year 2025 results showing operational improvements and a tighter cost base. Total net revenue was $49.2M in Q4 (down 21% YoY); operating loss narrowed to $6.3M; cash and investments were $302.6M with no debt.
The company realized $31M of targeted $70M cost savings and recorded $36.2M of restructuring charges in 2025, with remaining charges expected in early 2026. The company finalized a long‑term European license and supply agreement for VAZKEPA and retained U.S. VASCEPA market leadership.
Amarin (NASDAQ: AMRN) used American Heart Month (Feb 23, 2026) to urge urgent action on underutilized, guideline‑supported cardiovascular therapies.
The company highlighted that 48.9% of U.S. adults live with CVD and cited evidence that cumulative CV event incidence can reach ~40% over 10 years, calling to “Review, Reassess, Refocus” care to close treatment gaps.
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.
Amarin (NASDAQ: AMRN) commented on recent therapeutic advances for patients with elevated triglycerides and said its VASCEPA/VAZKEPA (icosapent ethyl) franchise is well positioned to benefit from broader category commercialization. The company noted VASCEPA has been prescribed >25 million times, is FDA approved for severe hypertriglyceridemia (TG ≥500 mg/dL) and for cardiovascular risk reduction as an adjunct to statin therapy, and cited REDUCE-IT results showing a 25% relative reduction in cardiovascular events in 8,179 patients. Amarin also highlighted a 2025 exclusive license with Recordati for commercialization across 59 countries, with VAZKEPA available in >20 countries.